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SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for 
controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 
(Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important 
unanswered questions remain, especially in patients with pre-existing conditions. In this position statement 
endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical 
Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 
vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. 
Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune 
responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF 
drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh 
these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in 
the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers 
of vaccine success.
Introduction
The COVID-19 pandemic is caused by a novel RNA 
coronavirus called severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).1,2 SARS-CoV-2 causes life-
threatening pneumonia, acute respiratory distress 
syndrome, and multi-organ failure,1,2 and has been 
responsible for a global health emergency. Effective 
treatment and prevention strategies are urgently 
needed. Vaccination is a key strategy to protect the 
health of the world’s population from COVID-19 and is 
likely to be especially important in high-risk individuals, 
such as those with pre-existing health conditions.3 
Without a vaccine, the WHO estimates that 80% of the 
world population will eventually become infected by 
this virus.
Inflammatory bowel disease (IBD), comprising Crohn’s 
disease and ulcerative colitis, is a typical immune-
mediated inflammatory disease, estimated to affect 
620 000 people in the UK, and its incidence continues to 
increase globally.4,5 As with other immune-mediated 
inflammatory diseases, patients with IBD may require 
immuno suppressive drugs, such as high-dose corti-
costeroids (≥20 mg prednisolone or equivalent), immuno-
modulators (thiopurines, metho trexate, and calcineurin 
inhibitors), anti-cytokine therapies (including anti-TNF 
and anti-IL-12p40 drugs), anti-integrin therapies 
(vedolizumab), and small-molecule inhibitors of sig-
nalling (tofacitinib), which could leave them suscep tible 
to infection.6,7 Concerns about the health of patients with 
immune-mediated inflammatory diseases during the 
COVID-19 pandemic has led to the introduction of radical 
and unprecedented health policies, including mandatory 
prolonged physical distancing measures, such as 
shielding. However, the risks associated with immuno-
suppression are not limited to increased susceptibility to 
infection. Immunosuppressive drugs may reduce the 
effectiveness of some vaccines, which could have major 
implications for the safety of immuno suppressed patients 
in the COVID-19 era.
Key messages
1 We strongly support SARS-CoV-2 vaccination for patients 
with inflammatory bowel disease (IBD)
2 The risks of SARS-CoV-2 vaccination in patients with IBD 
are anticipated to be very low
3 In patients with IBD taking immunosuppressive drugs, 
including biologics and small-molecule inhibitors, the key 
concerns are related to the theoretical risk of suboptimal 
vaccine responses rather than vaccine side-effects
4 We recommend that patients with IBD accept whichever 
approved SARS-CoV-2 vaccination is offered to them, in 
accordance with UK Department of Health and Social Care 
and the Medicines and Healthcare products Regulatory 
Agency (MHRA) guidance
5 It is important that patients with IBD are offered 
consistent and unbiased advice. This will be disseminated 
through the British Society of Gastroenterology and 
Crohn’s & Colitis UK
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SARS-CoV-2 vaccines are an important opportunity to 
suppress viral transmission and protect individual 
patients from COVID-19. Several SARS-CoV-2 vaccines 
are in advanced clinical development, and currently there 
are three that are approved in the UK (table; figure 1). It is 
likely that additional vaccines will become available in the 
future. The BNT162b2 vaccine (Pfizer/BioNTech),8 the 
ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca),9 and 
the mRNA-1273 vaccine (Moderna)10 have been given 
authorisation for temporary supply by the UK Department 
of Health and Social Care and the Medicines and 
Healthcare products Regulatory Agency (MHRA) under 
Regulation 174 of the Human Medicine Regulations 2012.11–13 
A timeline of SARS-CoV-2 vaccine development is shown 
in the appendix (pp 2–3).
The effect of immunosuppression on SARS-CoV-2 
vaccines
Although the MHRA does not list immunosuppression as 
a contraindication to the BNT162b2, ChAdOx1 nCoV-19, or 
mRNA-1273 vaccines, it does indicate that there is a 
theoretical possibility that immunosuppressive drugs 
could reduce the effectiveness of the vaccines, based on 
evidence from studies looking at the effect of immuno-
suppression on the immunogenicity of vaccines used for 
other infectious diseases (figure 2). Infliximab mono-
therapy is linked to impaired induction of protective 
immunity following hepatitis B virus (HBV),16 hepatitis A 
virus (HAV),17 pneumococcal,14,21 and influenza18,22,23 
vaccination, which might be more pronounced when anti-
TNF therapy is combined with immunomodulators such 
as thiopurines or methotrexate.24,25 Vedolizumab, which 
has a gut-specific mechanism of action, does not hinder 
HBV or influenza vaccination, but is associated with 
impaired antibody responses to cholera toxin, admin-
istered orally.26 There is a lack of data for some of the newer 
drugs used in IBD, although lessons have been learned in 
other immune-mediated inflammatory diseases. For 
instance, in psoriasis, antibody responses to pneumococcal 
and tetanus vaccines are preserved, and possibly even 
enhanced in patients treated with ustekinumab, a 
monoclonal antibody that blocks the p40 subunit of IL-12 
and IL-23.25 In rheumatoid arthritis, tofacitinib results in 
diminished induction of protective immune responses to 
Pfizer/BioNTech8 Oxford/AstraZeneca9 Moderna10
Name BNT162b2 ChAdOx1 nCoV-19 mRNA-1273
Dosing schedule 2 doses, 21 days apart* 2 doses, 28 days apart* 2 doses, 28 days apart*
Mechanism mRNA encoding a genetically modified 
SARS-CoV-2 spike protein
Non-replicating adenovirus vector, 
containing SARS-CoV-2 spike protein
mRNA encoding a genetically modified 
SARS-CoV-2 spike protein
Storage (long term) –80°C to –60°C +2°C to +8°C –20°C
Reported efficacy 95% 70%† 94·5%
Safety No serious concerns. Two anaphylactoid 
reactions since MHRA approval and roll-out
No serious concerns No serious concerns
UK MHRA approval Emergency approval granted Dec 2, 2020 Emergency approval granted 
Dec 30, 2020
Emergency approval granted 
Jan 8, 2021
*In the UK, the Joint Committee on Vaccination and Immunisation has advised that the second dose of BNT162b2 can be given between 3 and 12 weeks after the first dose 
and the second dose of both mRNA-1273 and ChAdOx1 nCoV-19 can be given between 4 and 12 weeks after the first dose. †Pooled data from two trials: 62% efficacy in 
one study and 90% in another study in which first vaccination was given at half dose.
Table: Overview of published phase 3 SARS-CoV-2 vaccination studies
Figure 1: SARS-CoV-2 and currently approved vaccine mechanisms
Adenovirus vector vaccines are replication-incompetent viruses that have been engineered to express the SARS-CoV-2 spike protein to which the recipient immune 
system responds. Examples include ChAdOx1 nCoV-19, JNJ-78436735, and Sputnik-V. mRNA vaccines are delivered in a lipid nanoparticle that is taken up by cells, 
which translate the mRNA to generate spike protein. Examples include BNT162b2, mRNA-1273, and COVAC1.
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pneumococcal vaccination, but responses to influenza 
vaccination are maintained.27
Vaccination logistics in patients with IBD
The UK Joint Committee on Vaccination and 
Immunisation (JCVI) is responsible for advising which 
sectors of society are prioritised in national vaccination 
programmes. As of Dec 30, 2020, priority sequencing is 
based on providing protection to individuals most at risk 
of morbidity and mortality from COVID-19.28 Since 
mortality from COVID-19 increases exponentially with 
age, the initial JCVI prioritisation is primarily age-based. 
The order of priority for phase one of the vaccination 
programme is shown in the panel.
In keeping with the British Society of Gastroenterology 
(BSG) risk grid,29 it is anticipated that patients with IBD 
who are younger than 65 years and in the moderate BSG 
risk category will fall into category 6 (individuals aged 
16–64 years with underlying health conditions that put 
them at higher risk of serious disease and mortality). 
Patients with IBD in the BSG high-risk category, including 
those with other comorbidities such as diabetes, chronic 
respiratory disorders, or morbid obesity, will fall into 
category 4 (clinically extremely vulnerable individuals). 
Irrespective of their position in the BSG risk grid, patients 
with IBD who are resident in care homes (category 1), are 
front-line health and social care workers (category 2) or are 
aged 75 years or older (category 3) are further prioritised.
In phase 3 trials, efficacy data for the BNT162b2 vaccine 
were obtained based on two doses given 21 days apart. 
Corresponding data for the ChAdOx1 nCoV-19 vaccine 
and the mRNA-1273 vaccine were based on two doses 
given 28 days apart. However, in the context of the rapidly 
worsening epidemiology of COVID-19 in the UK in 
late 2020 and given data indicating high efficacy from the 
first dose of both the BNT162b2 vaccine and the ChAdOx1 
nCoV-19 vaccine, the JCVI is prioritising the delivery of 
the first dose of vaccine to as many eligible individuals 
Figure 2: Summary of studies of immunogenicity of vaccines in patients taking immunosuppressive therapies
(A) Pneumococcal vaccine response rate (response measured as a two-fold increase in anti-pneumococcal antibody titre) is reduced in patients administered 
anti-TNF monotherapy (58%) and immunomodulator and anti-TNF combination therapy (63%) relative to 5-ASA treated controls (89%).14 Asterisks denote 
statistically significant difference vs controls. (B) 2009 H1N1 influenza vaccination response rate (response measured as a ≥40% haemagluttinin inhibition [HI] titre) 
is attenuated in patients on immunomodulator and anti-TNF combination therapy (36%) relative to non-immunosuppressed controls (64%).18 Asterisk denotes 
statistically significant difference vs controls. (C) Heatmap adapted from studies of responses to vaccination in patients on immunomodulator or anti-TNF therapy 






























































































































Reduction in seroprotection (%)
0 25 50
Panel: The Joint Committee on Vaccination and 
Immunisation (JCVI) phase 1 priority groups28
1 Residents in a care home for older adults and their carers
2 All those 80 years of age and over and front-line health 
and social care workers
3 All those 75 years of age and over
4 All those 70 years of age and over, and clinically extremely 
vulnerable individuals
5 All those 65 years of age and over
6 All individuals aged 16 years to 64 years with underlying 
health conditions which put them at higher risk of serious 
disease and mortality*
7 All those 60 years of age and over
8 All those 55 years of age and over
9 All those 50 years of age and over
*The ChAdOx1 nCoV-19 (Oxford/AstraZeneca) vaccine is only authorised for use in 
those aged 18 years of age and over; however, JCVI is of the view that this vaccine may 
be used in those 16–17 years of age where there is no access or availability to an 
alternative approved COVID-19 vaccine.
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as possible. Consequently, in the UK the second dose of 
vaccine may be delivered between 3 and 12 weeks after 
the first dose of the BNT162b2 vaccine and between 4 and 
12 weeks after the first dose of the ChAdOx1 nCoV-19 
vaccine.28 At the time of writing, updated JCVI advice is 
pending for the mRNA-1273 vaccine. JCVI further advises 
that the same vaccine should be used for both doses and 
that switching between vaccines or missing the second 
dose is not advised.
The main priority with timing is administration of the 
vaccine at the earliest opportunity. This is especially 
important with health-care systems under considerable 
strain during vaccine roll out and it is recommended that 
patients with IBD accept the first available vaccine 
appointment offered. For most patients, active IBD should 
not be a barrier to vaccination, although in patients with 
severe IBD flares or those requiring hospitalisation, it may 
be preferable to consider a short delay pending recovery to 
prevent confusion arising from incorrect attribution of 
vaccine-related adverse effects to complications of acute 
illness, and vice versa.
Maintenance immunosuppression should not be 
withheld for vaccination and the timing of subcutaneous 
or intravenous IBD medications should not delay vacci-
nation. There is some evidence with annual influenza 
vaccination that the timing of anti-TNF administration 
does not significantly affect vaccination immuno-
genicity.30 High-dose systemic corticosteroids, particularly 
in combination with other immuno suppressants, may 
reduce vaccine immunogenicity, as has been observed 
with annual influenza vaccination.25 When possible, 
SARS-CoV-2 vaccination should be administered while 
patients are taking the lowest dose of systemic 
corticosteroid. These considerations should be interpreted 
in the context of individual cases and discussed with 
patients. In patients participating in IBD clinical trials, 
provisions for vaccination should be included in trial 
protocols and discussed with the sponsor.
Serology testing for SARS-CoV-2 is not necessary 
before administering vaccination, even in people with 
suspected or proven prior infection. Patients with IBD 
should receive both doses of SARS-CoV-2 vaccination, 
even if they have previously been infected with 
SARS-CoV-2, because data on whether individuals 
acquire sufficient immunity following COVID-19 are 
lacking, as are data on the duration and strength of 
acquired immunity. It is advised that vaccination is done 
at least 4 weeks after onset of COVID-19 symptoms or 
4 weeks from the first PCR-positive specimen in 
asymptomatic patients.31 Patients with IBD should be 
encouraged to have both the annual influenza and the 
SARS-CoV-2 vaccinations, although co-administration at 
the same visit is not advised. Other vaccines such as the 
influenza and pneumococcal vaccines should be 
scheduled at intervals of at least 7 days from SARS-CoV-2 
vaccination.31 Following SARS-CoV-2 vaccination, 
patients with IBD are currently advised to continue to 
follow existing guidance on social distancing or 
shielding, determined by their position in the BSG 
risk grid.29 Tips on SARS-CoV-2 vaccination in patients 
with IBD can be found in the appendix (p 4).
SARS-CoV-2 vaccination safety in patients with 
IBD
Patients with IBD will have many questions regarding 
vaccination and specific data to inform many of these 
concerns are not yet available. However, there are several 
factors that can offer some reassurance. There is a robust 
and comprehensive regulatory process in place and 
approval is only given when there are compelling safety 
data. Standards for testing and monitoring of vaccines are 
generally higher than for most other medical interventions 
due to their intended use in healthy individuals, in whom 
the level of acceptable risk is lower. The approved 
SARS-CoV-2 vaccines have been tested in tens of 
thousands of patients with safety profiles comparable to 
other vaccines commonly used in patients with IBD, and 
have been appraised by multiple independent regulators, 
including the MHRA, the European Medicines Agency, 
and the US Food and Drug Administration. The 
BNT162b2, ChAdOx1 nCoV-19, and mRNA-1273 vaccines 
have received regulatory approval, which applies to 
patients with IBD. Moreover, for all three vaccines, 
immunosuppression is not a contra indication. To date 
there are no studies reporting the effect of any 
SARS-CoV-2 vaccine specifically in patients with IBD, as 
these patient groups have been excluded from the phase 3 
vaccination studies. Nevert heless, insights into how 
different IBD therapies affect host immunity can be 
inferred from serological responses to other vaccination 
programmes. Notably, other commonly used vaccines 
(eg, influenza, HBV, HAV, etc) are also very low risk in 
patients with IBD, although they were never specifically 
trialled in patients with IBD before approval.
Regulatory approval is based on safety data generated 
from monitoring over 19 000 vaccine recipients for at least 
2 months after their second dose (serious side-effects 
from vaccines are very rare beyond this point). Side-effect 
profiles from SARS-CoV-2 vaccines are in line with events 
observed with other commonly used vaccines. Data from 
the BNT162b2 phase 3 trial, which enrolled more than 
40 000 individuals, the ChAdOx1 nCoV-19 phase 3 trials, 
which enrolled more than 23 000 participants, and the 
mRNA-1273 phase 3 trial, which enrolled more than 
30 000 individuals, demonstrated that mild local injection 
site reactions (eg, pain, redness, and swelling) and 
systemic features (fatigue, headache, chills) were 
common, but serious adverse events were rare.8–10 For 
instance, there were four serious adverse events in 
BNT162b2 recipients, 79 in ChAdOx1 nCoV-19 recipients, 
and 71 in mRNA-1273 recipients.8–10 Very rare events of 
neuroinflammatory disorder have been reported with the 
ChAdOx1 nCoV-19 vaccine, but a causative role has not 
been established.9 In the BNT162b2 phase 3 trial, there 
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were two deaths among BNT162b2 recipients (one from 
arteriosclerosis, one from cardiac arrest) and four deaths 
in placebo recipients (two from unknown causes, one 
from haemorrhagic stroke, and one from myocardial 
infarction), which were considered to be unrelated to the 
vaccine or placebo.8 There were four non-COVID-19 
related deaths in ChAdOx1 nCoV-19 trials, three in controls 
and one in the vaccine recipients (one death each from 
road traffic accident, blunt force trauma, homicide, and 
fungal pneumonia).9 All were considered unrelated to 
vaccination. Five deaths occurred in the mRNA-1273 trial, 
three in the placebo group (one from intra-abdominal 
perforation, one from cardio pulmonary arrest, and one 
from severe systemic inflam matory syndrome in a 
participant with chronic lymphocytic leukaemia and 
diffuse bullous rash) and two in the vaccine group (one 
from cardiopulmonary arrest and one by suicide); none 
were considered related to vaccination.10 In the event of 
patients experiencing significant side-effects related to 
vaccination, these should be reported through the 
Coronavirus Yellow Card reporting website. If common 
side-effects such as pain or fever are troublesome, they 
can be treated with analgesia or anti-pyretic medication 
such as paracetamol.
There are certain groups of patients with IBD in whom 
vaccination is not advised or should be considered on the 
basis of a benefit-versus-risk analysis. Vaccination is not 
currently approved in those younger than 16 years. This is 
because almost all children will have asymptomatic or 
very mild disease if affected by COVID-1932,33 and there are 
currently no data on the safety and efficacy of SARS-CoV-2 
vaccination in children. In pregnancy, the routine use of 
SARS-CoV-2 vaccines is not recommended due to the lack 
of safety data in this population.28 There is some evidence 
that severe COVID-19 may be associated with premature 
birth, but evidence currently suggests that infection 
during pregnancy poses no additional risk of fetal 
develop mental problems, nor increased risk of mis-
carriage.34,35 The JCVI advises that vaccination should be 
considered in pregnant women in whom the risk of 
exposure to SARS-CoV-2 is high and unavoidable, or in 
women with underlying health conditions that put them 
at very high risk of serious complications of COVID-19. 
In these cases, risk and benefit should be discussed with 
individual patients.28,36 The JCVI advises that breast-
feeding is not a contraindication to vaccination. The 
clinical need for immunisation should be considered and 
women informed about the absence of safety data for the 
vaccine in the context of breastfeeding.28,35 The BNT162b2, 
ChAdOx1 nCoV-19, and mRNA-1273 vaccines are contra-
indicated if there is a history of hypersensitivity to the 
active substance or any of the vaccine excipients. A history 
of an adverse reaction to other medications, including 
patients with IBD who have had severe immediate-onset 
anaphylaxis following biologic treatment, is not a 
contraindication to the BNT162b2, ChAdOx1 nCoV-19, or 
mRNA-1273 vaccines. Guidance on allergies for other 
SARS-CoV-2 vaccines will be issued by the MHRA as the 
vaccines are approved.
IBD disease activity following SARS-CoV-2 vaccination
Since SARS-CoV-2 vaccines have not been tested in 
patients with IBD it is not possible to judge whether 
vaccination will have an effect on IBD disease activity. 
However, no serious gastrointestinal side-effects to 
SARS-CoV-2 vaccinations have yet been reported. 
Furthermore, there are reassuring data from studies of 
patients with IBD receiving other commonly used 
vaccinations. In a trial of 96 patients with IBD admin-
istered 23-valent polysaccharide pneumococcal vaccine, 
there were no serious adverse events and no reported 
deteriorations in IBD disease activity.14 In a study 
of influenza H1N1 vaccination, just 12 (11%) of 
108 individuals enrolled had an increase of more than 
two points in either the Harvey Bradshaw Index (HBI) or 
Simple Colitis Clinical Activity Index during 6 months of 
follow up.18 Only three patients required consequent 
alteration in their IBD medication. There was no 
unvaccinated control group, making it difficult to 
determine whether these findings were truly associated 
with vaccination. In another study of trivalent influenza 
vaccination given to 255 patients with IBD, no significant 
variations in HBI or Mayo scores were seen during 
2 years of follow-up following vaccination.37
Research opportunities
We have identified some key research priorities with 
regard to SARS-CoV-2 vaccination in patients with IBD. 
In light of data showing impaired responses to 
pneumococcal, influenza, and other vaccines in patients 
with IBD on immunosuppression, there is a pressing 
need to understand whether different immuno sup-
pressive regimens impair the development of anti-
SARS-CoV-2 immunity in this high-risk population. 
Although routine serological testing of vaccine immuno-
genicity may not be available in all IBD units, where 
available this information could help to guide future 
studies regarding the need to implement mitigation 
strategies, such as administration of further booster 
doses of vaccine. This information might also help to 
inform advice given about physical distancing strategies, 
including shielding in the event of future surges in 
COVID-19. The emerging field of precision vaccination 
seeks to define how baseline features can predict which 
individual patients will respond to vaccination and to 
what extent.38 Baseline characteristics that have been 
investigated as predictors of vaccination response to other 
vaccines include germline genetics, host trans criptional 
responses, microbiome, metabolome, and particular 
immune features.38–43 Future research should use multi-
platform approaches to study bio markers predicting 
vaccination outcome. Finally, the uptake of recommended 
vaccines amongst patients with IBD has historically been 
suboptimal.44 There is a necessity for qualitative research 
For the Coronavirus Yellow Card 
reporting website see 
https://coronavirus-yellowcard.
mhra.gov.uk
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on attitudes towards SARS-CoV-2 vaccination in patients 
with IBD. Rates of acceptance of vaccination should also 
be tracked and reasons for non-uptake explored.
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